NY-ESO-1-Targeted Immunotherapy Competitor Analysis 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Competitor Analysis: NY-ESO-1-Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering.

This Competitive Intelligence report analyzes the competitive field of NY-ESO-1-Targeted Immunotherapies as of June 2018 in a tabulated format with structured listings of industry-relevant data.

The New York esophageal squamous cell carcinoma-1 (NY-ESO-1) is a human tumor antigen of the cancer/testis family (also known as cancer germ cell antigen) that has been successfully targeted in vaccine trials and in adoptive T-cell therapy trials for the treatment of several solid tumors. Its ability to elicit spontaneous humoral and cellular immune responses, together with its restricted expression pattern, have rendered it a good candidate target for cancer immunotherapy.

Cancer testis antigens are a unique class of tumor-associated antigens, because they are normally expressed in the adult male germ line, but not in other normal tissues, and are overexpressed in various malignancies. NY-ESO-1 being the most immunogenic among the cancer testis antigen family members. NY-ESO-1 spontaneously elicits humoral and cellular responses in many patients with cancer. Therefore, among tumor-associated antigens, it is one of the most promising antigens for immunotherapy, and different vaccines using NY-ESO-1 peptides, full-length NY-ESO-1 protein, or NY-ESO-1 DNA are being evaluated in clinical trials.

Transfer of T-cell receptors (TCRs) specific for tumor-associated antigens is another promising approach for cancer immunotherapy. NY-ESO-1 is expressed in 10 to 50% of metastatic melanomas, lung, breast, prostate, thyroid and ovarian cancers as well as between 70 and 80% of synovial cell sarcomas. Interim results from clinical studies of NY-ESO-1 specific TCR engineered T-cells suggest generally good tolerance with initial efficacy.

The report includes a compilation of currently active projects in research and development of vaccines, TCR-engineered T-cells, Cytotoxic T-Lymphocytes and recombinant antibodies and proteins targeting New York esophageal squamous cell carcinoma-1 (NY-ESO-1). In addition, the report lists company- and institution-specific R&D pipelines of NY-ESO-1-Targeted Immunotherapies.

Competitor projects are listed in a tabular format providing information on:

  • Drug Codes
  • Target/Mechanism of Action
  • Class of Compound
  • Company
  • Product Category
  • Indication
  • R&D Stage
  • Additional comments with a hyperlink leading to the source of information.

Key Topics Covered:

1. NY-ESO-1-Targeted Immunotherapy

  • NY-ESO-1 Selective Cancer Vaccines
  • NY-ESO-1 Specific, Multi-Target Cancer Vaccines
  • NY-ESO-1 Selective Adoptive Cell Therapy
  • NY-ESO-1 Specific, Multi-Target Adoptive Cell Therapy
  • NY-ESO-1 Selective Recombinant Antibodies & Proteins

2. Corporate & Institutional NY-ESO-1 Immunotherapy R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/tkht8n/nyeso1targeted?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs